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MaBACKGROUND Low mean transvalvular gradient (<40 mm Hg) and small aortic valve area (<1.0 cm2) in patients with
aortic stenosis (AS) and preserved left ventricular ejection fraction raises uncertainty about the actual severity of the
stenosis and survival beneﬁt of aortic valve replacement (AVR).
OBJECTIVES This study analyzed studies of mortality and survival impact of AVR in patients with low-gradient (LG) AS
and preserved left ventricular ejection fraction, including paradoxical low-ﬂow (i.e., stroke volume index <35 ml/m2), low-
gradient (LF-LG) and normal-ﬂow, low-gradient (NF-LG), and those with high-gradient ($40 mm Hg) AS or moderate AS.
METHODS Studies published between 2005 and 2015 were analyzed. Primary outcome was the survival beneﬁt asso-
ciated with AVR. Secondary outcome was overall mortality regardless of treatment.
RESULTS Eighteen studies were included in the analysis. Patients with LF-LG AS have increased mortality compared
with patients with moderate AS (hazard ratio [HR]: 1.68; 95% conﬁdence interval [CI]: 1.31 to 2.17), NF-LG (HR: 1.80;
95% CI: 1.29 to 2.51), and high-gradient (HR: 1.67; 95% CI: 1.16 to 2.39) AS. AVR was associated with reduced mortality in
patients with LF-LG (HR: 0.44; 95% CI: 0.25 to 0.77). Similar beneﬁt occurred with AVR in patients with NF-LG
(HR: 0.48; 95% CI: 0.28 to 0.83). Compared with patients with high-gradient AS, those with LF-LG were less likely to be
referred to AVR (odds ratio: 0.32; 95% CI: 0.21 to 0.49).
CONCLUSIONS Patients with paradoxical LF-LG AS and NF-LG AS have increased risk of mortality compared
with other subtypes of AS with preserved left ventricular ejection fraction, and improved outcome with AVR.
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Thoracic Surgery guidelines generally recommend
aortic valve replacement (AVR) in patients with severe
aortic stenosis (AS) who have symptoms, left ventric-
ular (LV) systolic dysfunction (i.e., left ventricular
ejection fraction [LVEF] <50%), and/or undergo coro-
nary artery bypass graft surgery or other heart surgery
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AB BR E V I A T I O N S
AND ACRONYM S
AS = aortic stenosis
AVA = aortic valve area
AVR = aortic valve
replacement
CI = conﬁdence interval
HG = high gradient
HR = hazard ratio
LF = low ﬂow
LG = low gradient
LV = left ventricular
LVEF = left ventricular
ejection fraction
MAS = moderate aortic
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2595regarding the actual severity of the stenosis and the
potential indication for AVR if the patient is symp-
tomatic. This entity is often related to the presence of
low LV outﬂow. Indeed, given that the pressure
gradient is directly related to the squared function of
transvalvular ﬂow rate, even a modest decrease in
ﬂow rate can lead to an important reduction in
gradient and thus to an underestimation of stenosis
severity. This low-ﬂow, LG (LF-LG) condition may
occur in the context of either a reduced (i.e., classical
LF) or preserved (i.e., paradoxical LF) LVEF. Howev-
er, such discordance may also be observed in patients
with normal LVEF and ﬂow, in which case it may be
caused by measurement errors, a small body size, or
previously emphasized inherent inconsistencies in
the guidelines AVA/gradient criteria (3).SEE PAGE 2604
stenosis
NF = normal ﬂow
SAVR = surgical aortic valve
replacement
TAVR = transcatheter aortic
replacementAccording to current guidelines, AVR is recom-
mended in: 1) symptomatic patients with high-
gradient (HG) AS, regardless of their AVA, LVEF, or
ﬂow (Class I); 2) patients with classical (low LVEF) LF-
LG after conﬁrmation of stenosis severity by dobut-
amine stress echocardiography (Class IIa); or 3)
symptomatic patients with paradoxical (preserved
LVEF) LF-LG after conﬁrmation of stenosis severity
(Class IIa). The paradoxical LF-LG AS was described
for the ﬁrst time in 2007 (4) and the IIa recommen-
dation for AVR in these patients was added in the
2012/2014 edition of the guidelines (2,5). The studies
published before and after the publication of these
guidelines have, however, yielded conﬂicting results
with regard to the outcome and beneﬁt of AVR in the
patients with paradoxical LF-LG AS (6–11). Further-
more, the guidelines provide no speciﬁc recommen-
dation for the symptomatic patients with preserved
LVEF and normal-ﬂow, LG (NF-LG) AS, although
recent studies (12) suggest that an important propor-
tion of these patients have severe AS.
The objective of this meta-analysis was thus to
compare patients with LG AS and preserved LVEF,
including paradoxical LF-LG and NF-LG, with those
with HG AS or MAS with respect to overall mortality
and impact of AVR on survival.
METHODS
A literature search was performed in PubMed,
Embase, Ovid, and Google Scholar for studies pub-
lished between 2005 and 2015 without language re-
striction according to the following criteria: “low
gradient aortic stenosis” OR “paradoxical low ﬂow low
gradient aortic stenosis.” The related articles function
was used to broaden the search. The Cochrane librarywas also searched using the previously
mentioned terms. All the review articles
whose subject was LG AS and their reference
lists were also reviewed.
INCLUSION AND EXCLUSION CRITERIA. Ar-
ticles were included in the meta-analysis if
they included any of the following:
1. Comparison of overall mortality in patients
with LG (mean gradient <40 mm Hg with
AVA <1.0 cm2 and/or indexed AVA
<0.6 cm2/m2) or LF-LG (stroke volume
index <35 ml/m2 and gradient <40 mm Hg
with AVA <1.0 cm2 and/or indexed AVA
<0.6 cm2/m2) or NF-LG (stroke volume in-
dex >35 ml/m2 and gradient <40 mm Hg
with AVA <1.0 cm2 and/or indexed AVA
<0.6 cm2/m2) AS versus those with HG
(gradient $40 mm Hg) or MAS (gradient
<40 mm Hg with AVA >1.0 cm2 and/or
indexed AVA>0.6 cm2/m2). All groups have
preserved LVEF and patients with classical
(low LVEF) LF-LG AS were excluded from the
analysis.
2. Observational comparison of AVR (either surgical
aortic valve replacement [SAVR] or transcatheter
aortic valve replacement [TAVR]) versus conservative
management in patientswith LG, LF-LG, orNF-LGAS.
When the studies included in this meta-analysis re-
portedoutcomedataof patientswithHGASaccording
to treatment, AVR versus conservative management,
these results were included and analyzed.
The following exclusion criteria were used to select
the ﬁnal articles for the meta-analysis: <20 patients
in any group, and use of other criteria other than
recommended by the American College of Cardiology/
American Heart Association and European Society of
Cardiology/European Association for Cardio-Thoracic
Surgery guidelines (2,5) for the deﬁnition of severe
and/or LG AS.
The study sites and inclusion were compared to
ensure minimal patient overlap in different publica-
tions from the same site. If extensive overlap existed,
only the publication with the largest or diagnostically
most complete cohort (e.g., all patients instead of
only patients with AS) was included. In case studies
in which the outcome of AVR versus conservative
treatment of patients with LG AS is analyzed sepa-
rately from that of patients with LF-LG, both analyses
were included and considered as different studies for
the pooled analysis. LF (data for LF-LG) was added
after the name of the author in the forest plots.
OUTCOMES. Primary outcome was the survival
beneﬁt associated with AVR in patients with LG,
valve
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comparison of overall mortality, regardless of type of
treatment, in patients with LF-LG, NF-LG, HG, and
MAS. Datawere obtained fromunmatched populations
in the included studies to get the real-lifemortality risk
of the patients with the different AS entities. The
following variables were obtained to evaluate the
surgical and cardiovascular risk of each group: preva-
lence of female patients, age, coronary artery disease,
hypertension, diabetes, and renal failure.
STATISTICAL ANALYSIS. For each individual study,
hazard ratios (HRs) reﬂecting long-term mortality
along with their corresponding variances were calcu-
lated. When only the survival curves were available,
these were inspected and the overall mortality rates
were estimated using 6-month intervals using the
method of Parmar et al. (13). Overall log HRs using in-
verse variances as weights were then calculated for
each study. The odds ratio was used as the summary
statistic for categorical variables. For continuous var-
iables, the summary statistic chosen was the mean
difference.
Because of patient and treatment procedure het-
erogeneity in the included studies, random effects
model was used to calculate the summary statistics
and their 95% conﬁdence intervals (CIs). Meta-
analyses results are displayed in forest plots. Anal-
ysis was conducted using Review Manager Version 5.2
(The Cochrane Collaboration, Update Software, Ox-
ford, United Kingdom).
RESULTS
The search yielded 177 potential studies for analysis.
Of these, 74 articles did not compare outcomes among
groups as speciﬁed in the inclusion criteria, 34 arti-
cles were reviews or editorials, and 51 of them did not
address speciﬁcally the topic of investigation or did
not report the data required to analyze the primary or
secondary outcomes of the present study. The ﬁnal
total number of studies included in the meta-analysis
was 18 and the total number of patients was 7,459
(Table 1, Figure 1). None of these studies, except that
of Herrmann et al. (14), which was a post-hoc analysis
of the PARTNER-I (Placement of Aortic Transcatheter
Valves I) trial, contained a randomized comparison of
AVR versus conservative treatment. These articles
comprised a total of 1,012 patients with MAS (59%
were symptomatic, 35% underwent AVR), 3,056 pa-
tients with HG (75% symptomatic, 70% AVR), and
3,391 patients with LG AS (56% symptomatic, 58%
AVR). Of the latter subset, 1,353 patients had LF-LG,
1,553 patients had NF-LG, and 581 patients had no
deﬁnition of the ﬂow status (LF vs. NF). Not all of theincluded articles reported both the primary and sec-
ondary outcomes speciﬁed previously (Figure 1).
OVERALL MORTALITY. Patients with LF-LG AS have
increased global risk of death compared with patients
with MAS (HR: 1.68; 95% CI: 1.31 to 2.17) and those
with NF-LG (HR: 1.80; 95% CI: 1.29 to 2.51) (Figure 2).
The LF-LG patients also had higher risk of mortality
compared with those with HG AS (HR: 1.67; 95% CI:
1.16 to 2.39). When patients with HG are compared
with thosewith NF-LG, no differenceswere foundwith
regard to mortality (HR: 1.12; 95% CI: 0.89 to 1.42).
Only 2 of the included studies reported outcome
data in HG AS versus MAS. As expected, both studies
found that HG AS is associated with increased risk
of mortality compared with MAS (Clavel et al. [6]:
HR: 5.82; 95% CI: 3.92 to 8.64; Tribouilloy et al. [11]:
HR: 1.74; 95% CI: 1.27 to 2.39).
SURVIVAL BENEFIT WITH AVR. In patients with
LF-LG who undergo AVR, mortality was reduced by
56% (HR: 0.44; 95% CI: 0.25 to 0.77) (Figure 3). Similar
survival beneﬁt was obtained after AVR in patients
with NF-LG (HR: 0.48; 95% CI: 0.28 to 0.83). When we
included all studies that reported survival in LG AS
irrespective of ﬂow, patients who underwent AVR
had reduced risk of overall mortality (HR: 0.44;
95% CI: 0.33 to 0.58). Patients with HG AS displayed
the greatest survival beneﬁt with AVR (HR: 0.25;
95% CI: 0.19 to 0.35). Compared with patients with HG
AS, those with LF-LG were less likely to be referred to
AVR (odds ratio: 0.32; 95% CI: 0.21 to 0.49) (Figure 4).
Only 2 studies (6,11) reported data of AVR versus
conservative management in patients with MAS and
these 2 studies did not ﬁnd any signiﬁcant beneﬁt of
AVR on survival in these patients (Clavel et al. [6]:
HR: 0.44; 95% CI: 0.17 to 1.12; and Tribouilloy et al.
[11]: HR: 0.66; 95% CI: 0.36 to 1.22).
COMPARISON OF PATIENT BASELINE CHARACTER-
ISTICS. Compared with patients with HG, those with
LF-LG and those with NF-LG AS were older and had
higher prevalence of coronary artery disease, dia-
betes, and hypertension (Online Figures S1 to S4).
Patients with LF-LG had similar baseline characteris-
tics compared with patients NF-LG (Online Figures S5
and S6).
Among patients with LF-LG AS, those who under-
went AVR were older, were predominantly men, and
had higher prevalence of renal failure (Online
Figures S7 and S8).
DISCUSSION
The main ﬁndings of this meta-analysis are: 1) patients
with LF-LG AS have higher risk of overall mortality
TABLE 1 Description of Included Studies
First Author, Year (Ref. #) Criteria for the Deﬁnition of LF/LG
Number of Patients
SAVR/
TAVR
Symptomatic
Status (%)
HG
(AVR%)
LF-LG
(AVR%)
NF-LG
(AVR%)
LG
(AVR%)
Pai et al., 2008 (16) AVA #0.8 cm2, MG <30 mm Hg 52 (35) SAVR ND
Belkin et al., 2011 (17) AVA #1 cm2, MG <30 mm Hg 67 (49) 94 (23) SAVR S (54), A (46)
Jander et al., 2011 (23) AVA #1 cm2, MG <40 mm Hg,
SVI <35 ml/m2
223 (41) 212 (43) 435 (42) SAVR A
Tarantini et al., 2011 (18) AVA #1 cm2, peak-to-peak
gradient <30 mm Hg,
SVI <35 ml/m2
20 82 102 (72) SAVR S (88), A (12)
Clavel et al., 2012 (6) iAVA #0.6 cm2/m2, MG <40 mm Hg,
SVI <35 ml/m2
187 (80) 187 (44) 187 (44) SAVR S (71), A (29)
Eleid et al., 2013 (21) iAVA #0.6 cm2/m2, MG <40 mm Hg,
SVI <35 ml/m2
1299 (69) 53 (49) 352 (40) 405 (41) SAVR S (62), A (38)
Herrmann et al., 2013 (14) AVA #0.8 cm2, MG <40 mm Hg,
SVI <35 ml/m2
52 (44) 52 (44) TAVR S
Le Ven et al., 2013 (31) iAVA #0.6 cm2/m2, MG <40 mm Hg,
SVI <35 ml/m2
195 (100) 86 (100) 110 (100) 196 (100) TAVR S
Mehrotra et al., 2013 (8) AVA #1 cm2, MG <40 mm Hg,
SVI <35 ml/m2
38 75 113 S (26), A (74)
Melis et al., 2013 (9) AVA #1 cm2, MG <40 mm Hg,
SVI <35 ml/m2
169 (66) 42 (45) 98 (53) 140 (51) SAVR ND
Mohty et al., 2013 (20) AVA #1 cm2, MG <40 mm Hg,
SVI <35 ml/m2
386 (94) 99 (84) 172 (87) 271 (86) SAVR S (89), A (11)
O’Sullivan et al., 2013 (33) iAVA #0.6 cm2/m2, MG <40 mm Hg,
SVI <35 ml/m2
208 (100) 85 (100) 85 (100) TAVR S (71), A (29)
Ozkan et al., 2013 (7) iAVA #0.6 cm2/m2, MG <40 mm Hg,
SVI <35 ml/m2
135 (40) 125 (55) 260 (47) SAVR S (93), A (7)
Grupper et al., 2014 (32) AVA #1 cm2, MG <40 mm Hg 113 303 416 (23) SAVR ND
Maes et al., 2014 (10) iAVA #0.6 cm2/m2, MG <40 mm Hg,
SVI <35 ml/m2
144 (42) 115 90 205 (33) SAVR S (37), A (63)
Parikh et al., 2015 (34) AVA #1 cm2/m2, MG <40 mm Hg,
SVI <35 ml/m2
536 (100) 152 (100) 688 (100) SAVR S (81), A (19)
Tribouilloy et al., 2015 (11) iAVA #0.6 cm2/m2, MG <40 mm Hg,
SVI <35 ml/m2
247 (53) 57 (12) 85 (25) 142 (20) SAVR S (55), A (45)
Yamashita et al., 2015 (35) iAVA #0.6 cm2/m2, MG <40 mm Hg,
SVI <35 ml/m2
154 19 61 80 S (46), A (54)
A ¼ asymptomatic; AVA ¼ aortic valve area; AVR ¼ aortic valve replacement; HG ¼ high-gradient; iAVA ¼ indexed aortic valve area; LF-LG ¼ low-ﬂow, low-gradient; MG ¼ mean gradient;
NF-LG ¼ normal-ﬂow, low-gradient; ND ¼ not determined; S ¼ symptomatic; SAVR ¼ surgical aortic valve replacement; SVI ¼ stroke volume index; Symptom status ¼ symptomatic status
reported by authors; TAVR ¼ transcatheter aortic valve replacement.
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2597compared with those with MAS, NF-LG AS, and HG AS;
2) patients with NF-LG AS have higher risk of mortality
compared with patients with MAS but similar risk
compared with patients with HG AS; and 3) SAVR/
TAVR improves overall survival in patients with LF-LG
and in those with NF-LG AS (Central Illustration).
OUTCOMES AND IMPACT OF AVR IN PARADOXICAL
LF-LG AS. A relatively large proportion (30% to 50%)
of AS patients with preserved LVEF have LF (stroke
volume index <35 ml/m2) and because of the LF state,
these patients often have a LG despite the presence
of severe stenosis. The high prevalence of LF in the AS
population is not necessarily surprising given that this
population is predominantly elderly, with frequent
comorbidities (systemic hypertension, coronary ar-
tery disease, diabetes, atrial ﬁbrillation, mitral regur-
gitation, tricuspid regurgitation, mitral stenosis) and
associated complications (pronounced LV concentricremodeling, impaired LV diastolic ﬁlling, ventricular
dyssynchrony, impaired LV systolic longitudinal
function). These comorbidities and associated com-
plications may all contribute to reduce stroke volume
and increase risk of mortality and morbidity. Accord-
ingly, in most previous studies (4,6,8,15–22), patients
with paradoxical LF-LG AS had worse symptomatic
status and prognosis compared with those with MAS,
NF-LG, or HG AS. However, some studies (10,11,23)
found similar prognoses for LF-LG patients versus
those with MAS, NF-LG, or HG AS.
LF-LG AS is a highly heterogeneous entity and the
discrepancies between previous studies may be
related to differences in the baseline characteristics
of the study populations and in the Doppler-
echocardiographic methods and deﬁnitions used to
identify LF-LG AS (4,6–8,10,21,23–25). These factors
may also explain why the prevalence of LF-LG AS
FIGURE 1 Flow Chart for Inclusion of the Studies
Initial search results for
LF-LG AS or Paradoxical LF-LG
AS (n=177)
74 articles did not compare
between gradient subgroups
36 articles were reviews or
editorials
49 articles did not address the
investigated subject, did not
report the main or secondary
outcome
Total of included studies
(n=18)
LF-LG (AVR vs Cons)
(n=8)
LG (AVR vs Cons)
(n=14)
NF-LG (AVR vs Cons)
(n=7)
HG (AVR vs Cons)
(n=6)
LF-LG vs HG
(n=9)
NF-LG vs HG
(n=6)
LF-LG vs NF-LG
(n=8)
LF-LG vs MAS
(n=5)
AS ¼ aortic stenosis; AVR ¼ aortic valve replacement; Cons ¼ conservative treatment; HG ¼ high-gradient; LF-LG ¼ low-ﬂow, low-gradient;
LG ¼ low-gradient; MAS ¼ moderate aortic stenosis; NF-LG ¼ normal-ﬂow, low-gradient.
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2598varies extensively from one study to the other (5% to
35%) (3,4,10,11,16,20,21,26).
With low transvalvular ﬂow, the forces applied
against the valve cusps may not be sufﬁcient to
completely open a valve that is mildly or moderately
stenotic. This “pseudosevere” AS phenomenon may
occur with both classical and paradoxical LF-LG.
Previous studies report that 30% to 50% of patients
with paradoxical LF-LG AS have pseudosevere AS
(12,27,28). Hence, discrepancies among previous
studies with regard to the outcomes and survival
beneﬁt of AVR in patients with paradoxical LF-LG
may also be, at least in part, related to differences
in the proportion of patients with pseudosevere
versus true severe AS included in each study. None-
theless, the pooled analysis of the present study
conﬁrms that overall, paradoxical LF-LG AS is asso-
ciated with increased risk of mortality compared
with the other subtypes of AS with preserved LVEF.
These ﬁndings also emphasize the importance of
conﬁrming the presence of severe stenosis before
considering AVR in these patients, as recommended
in the guidelines (2,5). Assessment of the morpho-
logical changes of the aortic valve (i.e., calciﬁcation,
thickening) by transthoracic or transesophageal
echocardiography, low-dose dobutamine stress
echocardiography, or quantitative aortic valve cal-
cium scoring by multidetector computed tomography
may be used for this purpose (12,27,29).The present study conﬁrms that AVR is associated
with a major survival beneﬁt in patients with para-
doxical LF-LG AS. Few studies (10,11,23) did not ﬁnd a
signiﬁcant beneﬁt of AVR, but most of these studies
were underpowered for this speciﬁc analysis. The
present study also conﬁrms that patients with LF-LG
are less often referred to AVR compared with those
with HG AS. The presence of LG may result in un-
derestimation of the stenosis severity and thus in
underuse of AVR in patients with paradoxical LF-LG
AS. This may have contributed to the increased risk
of mortality observed in this subset.
Hence, the results of the present study provide
further support to the Class IIa recommendation for
AVR in symptomatic patients with paradoxical LF-LG
severe AS.
OUTCOMES AND IMPACT OF AVR IN NF-LG AS. Al-
though patients with NF-LG AS represent an impor-
tant proportion (25% to 50%) of the AS population
with preserved LVEF (3,7,8,11,21,30), the guidelines
do not address the situation of these patients. As
with LF-LG, NF-LG AS is also a highly heterogeneous
entity that includes: 1) patients with errors in the
measurement of the stroke volume, AVA, and/or
gradient; 2) patients with small body size; and 3)
patients with inconsistent grading. The latter cate-
gory likely represents the largest proportion of the
patients with NF-LG AS. From a ﬂuid mechanics
standpoint and if LV ﬂow is normal, the cutpoint
FIGURE 2 Overall Mortality in the Different Subtypes of Flow/Gradient Aortic Stenosis
High gradient (HG) vs Low-flow low-gradient (LF-LG) aortic stenosis
Study or Subgroup log[Hazard Ratio] SE Weight
Hazard Ratio
IV, Random, 95% CI
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Moderate (MAS) vs Low-flow low-gradient (LF-LG) aortic stenosis
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Heterogeneity: Tau2 = 0.03; Chi2 = 7.29, df = 5 (P = 0.20); I2 = 31%
Test for overall effect: Z = 0.99 (P = 0.32)
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Le Ven et al 2013
Maes et al 2014
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Mohty et al 2013
Ozkan et al 2013
Tribouilloy et al 2015
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1.1861
0.4517
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0.4178
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0.2293
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0.4547
0.4638
0.1802
0.2647
0.3364
14.5%
14.4%
14.7%
8.1%
7.9%
16.0%
13.2%
11.1%
3.72 [2.38, 5.81]
1.77 [1.13, 2.77]
0.91 [0.59, 1.40]
3.27 [1.34, 7.98]
1.57 [0.63, 3.90]
1.69 [1.19, 2.41]
1.65 [0.98, 2.77]
1.52 [0.79, 2.94]
Total (95% CI) 100.0% 1.80 [1.29, 2.51]
Heterogeneity: Tau2 = 0.15; Chi2 = 22.15, df = 7 (P = 0.002); I2 = 68%
Test for overall effect: Z = 3.46 (P = 0.0005)
Clavel et al 2012
Jander et al 2011
Mehrotra et al 2013
Tribouilloy et al 2015
Yamashita et al 2015
0.5142
0.451
1.0623
0.4443
–0.6933
0.1781
0.316
0.4984
0.2695
2.3527
53.0%
16.8%
6.8%
23.1%
0.3%
1.67 [1.18, 2.37]
1.57 [0.85, 2.92]
2.89 [1.09, 7.68]
1.56 [0.92, 2.64]
0.50 [0.00, 50.30]
Total (95% CI) 100.0% 1.68 [1.31, 2.17]
Heterogeneity: Tau2 = 0.00; Chi2 = 1.58, df = 4 (P = 0.81); I2 = 0%
Test for overall effect: Z = 4.02 (P < 0.0001)
0.1 0.2 0.5 1 2 5 10
HG NF-LG
0.1 0.2 0.5 1 2 5 10
NF-LG LF-LG
0.2 0.5 1 2 5
MAS LF-LG
A
B
C
D
Comparison of risk of overall mortality in LF-LG versus HG (A), NF-LG versus HG (B), LF-LG versus NF-LG (C), and LF-LG versus MAS (D). CI ¼ conﬁdence
interval; DF ¼ degrees of freedom; IV ¼ inverse variance; SE ¼ standard error; other abbreviations as in Figure 1.
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2599value of AVA of 1.0 cm2 proposed in the guidelines to
deﬁne severe AS indeed corresponds more precisely
to a mean gradient around 30 to 35 mm Hg rather than
to the 40 mm Hg cutpoint given in the guidelines (3).
Hence, patients with NF-LG AS are generally in themoderate-to-severe stenosis range and, accordingly,
recent studies (12) reported that about 50% of these
patients may have hemodynamically severe stenosis.
There are no data about the natural history of NF-LG
AS. However, it is possible that some patients with
FIGURE 3 Impact of Aortic Valve Replacement on Survival
Survival in patients with low-flow low-gradient (LF-LG) aortic stenosis
Study or Subgroup log[Hazard Ratio] SE Weight
Hazard Ratio
IV, Random, 95% CI
Hazard Ratio
IV, Random, 95% CI
Belkin et al 2011
Clavel et al 2012
Eleid et al 2013
Grupper et al 2014
Herrmann et al 2013
Jander et al 2011
Maes et al 2014
Melis et al 2012
Mohty et al 2013
Ozkan et al 2013
Ozkan LF
Pai et al 2008
Tarantini et al 2011
Tarantini LF
Tribouilloy et al 2015
Yamashita et al 2015
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–1.4697
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–0.4539
–0.9113
–1.3243
–2.3645
–0.2525
–1.3218
0.6902
0.2758
0.3572
0.2707
0.4066
0.7269
0.4079
0.5269
0.4787
0.2855
0.1668
0.884
0.3575
0.8725
0.9529
816.4965
0.0%
17.9%
15.9%
0.0%
0.0%
8.5%
0.0%
12.0%
13.0%
0.0%
20.3%
0.0%
0.0%
6.7%
5.9%
0.0%
0.49 [0.13, 1.89]
0.32 [0.19, 0.56]
0.29 [0.14, 0.58]
0.51 [0.30, 0.87]
0.45 [0.20, 1.00]
0.84 [0.20, 3.47]
0.47 [0.21, 1.05]
2.31 [0.82, 6.50]
0.23 [0.09, 0.59]
0.49 [0.28, 0.86]
0.64 [0.46, 0.88]
0.40 [0.07, 2.27]
0.27 [0.13, 0.54]
0.09 [0.02, 0.52]
0.78 [0.12, 5.03]
0.27 [0.00, Not estimable]
Total (95% CI) 100.0% 0.46 [0.27, 0.79]
Heterogeneity: Tau2 = 0.33; Chi2 = 22.35, df = 7 (P = 0.002); I2 = 69%
Test for overall effect: Z = 2.85 (P = 0.004) 0.02 0.1 1 10 50
AVR Conservative
Survival in patients with normal-flow low-gradient (NF-LG) aortic stenosis
Study or Subgroup log[Hazard Ratio] SE Weight
Hazard Ratio
IV, Random, 95% CI
Hazard Ratio
IV, Random, 95% CI
Survival in patients with low-gradient (LG) aortic stenosis
Study or Subgroup log[Hazard Ratio] SE Weight
Hazard Ratio
IV, Random, 95% CI
Hazard Ratio
IV, Random, 95% CI
Survival in patients with high-gradient (HG) aortic stenosis
Study or Subgroup log[Hazard Ratio] SE Weight
Hazard Ratio
IV, Random, 95% CI
Hazard Ratio
IV, Random, 95% CI
Eleid et al 2013
Jander et al 2011
Melis et al 2012
Mohty et al 2013
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Tribouilloy et al 2015
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–0.3001
–1.5424
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17.7%
8.4%
16.3%
16.9%
15.3%
16.5%
8.9%
1.16 [0.70, 1.93]
0.45 [0.11, 1.90]
0.74 [0.39, 1.39]
0.21 [0.12, 0.38]
0.40 [0.20, 0.82]
0.32 [0.17, 0.58]
0.57 [0.14, 2.26]
Total (95% CI) 100.0% 0.48 [0.28, 0.83]
Heterogeneity: Tau2 = 0.36; Chi2 = 23.03, df = 6 (P = 0.0008); I2 = 74%
Test for overall effect: Z = 2.65 (P = 0.008) 0.02 0.1 1 10 50
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0.51 [0.30, 0.87]
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0.47 [0.21, 1.05]
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0.23 [0.09, 0.59]
0.49 [0.28, 0.86]
0.64 [0.46, 0.88]
0.40 [0.07, 2.27]
0.27 [0.13, 0.54]
0.09 [0.02, 0.52]
0.78 [0.12, 5.03]
0.27 [0.00, Not estimable]
Total (95% CI) 100.0% 0.45 [0.35, 0.59]
Heterogeneity: Tau2 = 0.11; Chi2 = 25.84, df = 15 (P = 0.04); I2 = 42%
Test for overall effect: Z = 5.71 (P < 0.00001) 0.02 0.1 1 10 50
AVR Conservative
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Tribouilloy et al 2015
–0.3532
–2.3106
–1.4036
–1.3096
–1.5845
–1.2379
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0.4353
0.0185
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0.2437
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9.7%
37.5%
13.1%
10.7%
19.9%
0.70 [0.29, 1.72]
0.10 [0.04, 0.23]
0.25 [0.24, 0.25]
0.27 [0.14, 0.54]
0.21 [0.09, 0.46]
0.29 [0.18, 0.47]
Total (95% CI) 100.0% 0.25 [0.19, 0.35]
Heterogeneity: Tau2 = 0.07; Chi2 = 10.37, df = 5 (P = 0.07); I2 = 52%
Test for overall effect: Z = 8.69 (P < 0.00001)
A
B
C
D
(A to D) Impact of AVR on survival in the different subtypes of ﬂow/gradient aortic stenosis. Abbreviation as in Figures 1 and 2.
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FIGURE 4 Referral to AVR in Patients With LF-LG and HG Severe Aortic Stenosis
Low-flow low-gradient (LF-LG) vs high gradient (HG)
Study or Subgroup
LF-LG HG Odds Ratio Odds Ratio
Events Total Events Total Weight M–H, Random, 95% CI M–H, Random, 95% CI
Belkin et al 2011
Clavel et al 2012
Eleid et al 2013
Maes et al 2014
Melis et al 2013
Mohty et al 2013
Tribouilloy et al 2015
22
82
26
68
19
83
7
94
187
53
205
45
99
57
33
150
896
60
112
363
131
67
187
1299
144
166
386
247
13.5%
16.3%
15.1%
16.6%
13.5%
13.4%
11.6%
0.31 [0.16, 0.62]
0.19 [0.12, 0.31]
0.43 [0.25, 0.75]
0.69 [0.45, 1.08]
0.35 [0.18, 0.69]
0.33 [0.17, 0.65]
0.12 [0.05, 0.28]
Total (95% CI) 740 2496 100.0% 0.32 [0.21, 0.49]
Total events 307 1745
Heterogeneity: Tau2 = 0.24; Chi2 = 22.50, df = 6 (P = 0.0010); I2 = 73%
Test for overall effect: Z = 5.16 (P < 0.00001) 0.01 0.1 1 10 100LF-LG HG
M-H ¼ Mantel Haenszel; other abbreviations as in Figures 1 and 2.
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2601NF-LG AS may progress to HG AS, whereas others may
evolve to LF-LG AS.
The present meta-analysis reveals that the out-
come of the patients with NF-LG AS is similar to thatCENTRAL ILLUSTRATION Outcome and Impact of Aortic
Flow/Gradient Aortic Stenosis
Dayan, V. et al. J Am Coll Cardiol. 2015; 66(23):2594–
Pooled odds ratio for the different groups and modalities of treatment.
gradient; LF-LG ¼ low-ﬂow, low-gradient; LG ¼ low-gradient; MAS ¼ mof patients with HG AS and better compared with
patients with LF-LG AS. Furthermore, AVR was
associated with improved survival in patients with
NF-LG. Hence, in light of these results, conﬁrmationValve Replacement in the Different Subtypes of
603.
AS ¼ aortic stenosis; AVR ¼ aortic valve replacement; HG ¼ high-
oderate aortic stenosis; NF-LG ¼ normal-ﬂow, low-gradient.
PERSPECTIVES
COMPETENCY IN MEDICAL KNOWLEDGE:
Patients with paradoxical low-ﬂow, low-gradient
severe AS and preserved LV ejection fraction have
higher risk of mortality compared with other aortic
stenosis subtypes.
COMPETENCY IN PATIENT CARE AND
PROCEDURAL SKILLS: AVR improves survival in
patients with paradoxical low-ﬂow, low-gradient and
in those with normal-ﬂow, low-gradient severe AS.
TRANSLATIONAL OUTLOOK: Further studies are
needed to understand the pathophysiological mech-
anisms responsible for low-gradient severe AS and
derive improved methods for clinical risk stratiﬁcation
for patients with this condition.
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2602of stenosis severity with additional diagnostic tests
should probably be considered in patients with NF-LG
AS who are symptomatic.
STUDY LIMITATIONS. We did not use individual data,
therefore results and conclusions drawn from meta-
regression analysis regarding independent predictors
should be interpreted cautiously. In the context of a
meta-analysis, it is generally not possible to obtain
individual data. It is therefore impossible to adjust
the analyses of outcomes for potential confounding
variables. In particular, it was not possible to assess
the impact of symptomatic status on outcomes and
beneﬁt of AVR in the different subtypes of AS.
Observational comparisons of AVR with conserva-
tive treatment were nonrandomized and therefore
subject to confounding by indication bias. In par-
ticular, some patients with severe AS and severe
comorbidities may have been considered at too high
risk for AVR and therefore left on conservative man-
agement. This bias may thus have overestimated the
beneﬁt of AVR.
CONCLUSIONS
Patients with paradoxical LF-LG AS have increased
risk of mortality compared with all other subtypes of
severe AS with preserved LVEF, and their outcome is
improved by AVR. These ﬁndings support the guide-
lines recommendation (Class IIa) for AVR in these
patients when they are symptomatic and when severe
stenosis is the most likely cause of symptoms.
Furthermore, patients with NF-LG also had similar
risk of mortality compared with those with HG AS and
their outcome was improved by AVR. These ﬁndingssuggest symptomatic patients with NF-LG should also
receive particular attention and that additional diag-
nostic tests should be considered in these patients to
corroborate the stenosis severity and determine the
indication for AVR.
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